Tegaserod

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Opioid-induced Constipation

Conditions

Opioid-induced Constipation

Trial Timeline

Nov 1, 2006 → Apr 1, 2007

NCT ID

NCT00399659

About Tegaserod

Tegaserod is a phase 3 stage product being developed by Novartis for Opioid-induced Constipation. The current trial status is terminated. This product is registered under clinical trial identifier NCT00399659. Target conditions include Opioid-induced Constipation.

What happened to similar drugs?

4 of 20 similar drugs in Opioid-induced Constipation were approved

Approved (4) Terminated (7) Active (10)

✅Naldemedine + PlaceboShionogiApproved

✅methylnaltrexone + placeboBausch HealthApproved

✅Methylnaltrexone bromideBausch HealthApproved

✅Methylnaltrexone + PlaceboBausch HealthApproved

🔄Naldemedine + PlaceboShionogiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00511771	Pre-clinical	Completed	—	—	Irritable Bowel Syndrome With Constipation
NCT00414024	Phase 3	Terminated	Feb 1, 2007	May 1, 2007	Opioid-induced Constipation
NCT00390975	Approved	Terminated	Jan 1, 2007	Mar 1, 2007	Gastroparesis
NCT00399659	Phase 3	Terminated	Nov 1, 2006	Apr 1, 2007	Opioid-induced Constipation
NCT00365820	Phase 2/3	Terminated	Jul 1, 2006	Apr 1, 2007	Constipation
NCT00348634	Approved	Terminated	Jul 1, 2006	Apr 1, 2007	Chronic Constipation
NCT00171457	Phase 3	Completed	Apr 1, 2005	Sep 1, 2006	Heartburn
NCT00171470	Phase 3	Completed	Apr 1, 2005	Aug 1, 2006	Dyspepsia
NCT00139568	Phase 3	Completed	Feb 1, 2005	Oct 1, 2005	Constipation
NCT00563758	Pre-clinical	Terminated	Dec 1, 2004	Feb 1, 2006	Constipation
NCT00563615	Pre-clinical	UNKNOWN	Nov 1, 2004	Oct 1, 2006	Constipation
NCT00171431	Phase 3	Terminated	Nov 1, 2004	May 1, 2006	Constipation Predominant
NCT00232037	Phase 3	Completed	Sep 1, 2004	Aug 1, 2006	Dyspepsia
NCT00232102	Phase 3	Completed	Sep 1, 2004	Aug 1, 2006	Dyspepsia
NCT00232089	Phase 3	Completed	May 1, 2004	Jun 1, 2006	Dyspepsia
NCT00142974	Phase 2	Terminated	May 1, 2004	Apr 1, 2005	Diabetic Gastropathy
NCT00142987	Approved	Completed	Apr 1, 2004	Jun 1, 2005	IBS-C and IBS With Mixed Bowel Habits
NCT00149877	Approved	Completed	Apr 1, 2004	Feb 1, 2006	Chronic Constipation
NCT00141089	Phase 3	Completed	Mar 1, 2004	Feb 1, 2005	Chronic Constipation
NCT00171483	Phase 3	Completed	Jan 1, 2004	Apr 1, 2005	Gastroesophageal Reflux Disease (GERD)

Competing Products

20 competing products in Opioid-induced Constipation

See all competitors

Product	Company	Stage	Hype Score
Naldemedine + Placebo	Shionogi	Phase 3	40
Naldemedine + Placebo	Shionogi	Approved	50
Naldemedine	Shionogi	Phase 1/2	39
Naldemedine + Placebo	Shionogi	Phase 3	40
Placebo + Naldemedine	Shionogi	Phase 2	35
Naldemedine + Placebo	Shionogi	Phase 3	40
Naloxegol	Kyowa Kirin	Pre-clinical	26
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	32
NKTR-118 + Usual care	AstraZeneca	Phase 3	40
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
Naloxegol + Placebo Oral Capsule	AstraZeneca	Phase 2	27
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
Tegaserod	Novartis	Phase 3	32
Methylnaltrexone bromide + Placebo	Pfizer	Phase 2	35
ALKS 37 + Placebo	Alkermes	Phase 2	32